Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Stem Cells Transl Med ; 13(6): 515-521, 2024 Jun 14.
Article in English | MEDLINE | ID: mdl-38578768

ABSTRACT

BACKGROUND: Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment. The study evaluated the long-term safety and effectiveness of allogeneic ASCs in radiation-induced xerostomia among patients with previous oropharyngeal cancer. METHODS: This study constitutes 3-year follow-up on the original 10 patients who received allogeneic ASCs injections to the submandibular and parotid glands as part of the MESRIX-II trial. The MESRIX-II trial included the preliminary 4-month follow-up. The primary endpoint was long-term safety. Secondary endpoints were effectiveness evaluated by changes in salivary flow rate and patient-reported outcomes (PROs). Immune response was evaluated by assessing the development of donor-specific antibodies (DSA). FINDINGS: All 10 MESRIX-II patients completed the long-term follow-up (ie, no missing data). During the long-term follow-up, 2 patients encountered a significant adverse event, which was determined to be unrelated to the treatment. No DSAs were detectable at 3 years. The stimulated salivary flow rate increased significantly from an average of 0.66 mL/minute at baseline to 0.86 mL/minute at follow-up, corresponding to an increase of 0.20 [95% CI 0.08 to 0.30] mL/minute, or approximately 30%. Among the PROs, sticky saliva symptoms were reduced, with a -20.0 [95% CI -37.3 to -2.7] units. INTERPRETATION: In conclusion, this study is the first to present long-term follow-up outcomes of allogeneic ASC treatment as a therapeutic option for radiation-induced xerostomia. The study found that ASC treatment appears safe, and there were no indications of adverse immune responses at the 3-year follow-up. Further studies are warranted to evaluate the findings in larger settings.


Subject(s)
Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Xerostomia , Humans , Xerostomia/etiology , Xerostomia/therapy , Mesenchymal Stem Cell Transplantation/methods , Male , Female , Middle Aged , Aged , Mesenchymal Stem Cells/cytology , Follow-Up Studies , Transplantation, Homologous/methods , Treatment Outcome
2.
Stem Cell Rev Rep ; 20(4): 1078-1092, 2024 May.
Article in English | MEDLINE | ID: mdl-38430363

ABSTRACT

BACKGROUND: Mesenchymal stromal/stem cells (MSCs) have been suggested for salivary gland (SG) restoration following radio-induced salivary gland damage. This study aimed to determine the safety and effectiveness of MSC therapy on radio-induced SG damage and hypofunction in preclinical in vivo studies. METHODS: PubMed and EMBASE were systematically searched for preclinical in vivo interventional studies evaluating efficacy and safety of MSC treatment following radio-induced salivary gland damage published before 10th of January 2022. The primary endpoint was salivary flow rate (SFR) evaluated in a meta-analysis. The study protocol was published and registered on PROSPERO ( www.crd.ac.uk/prospero ), registration number CRD42021227336. RESULTS: A total of 16 preclinical in vivo studies were included for qualitative analysis (858 experimental animals) and 13 in the meta-analysis (404 experimental animals). MSCs originated from bone marrow (four studies), adipose tissue (10 studies) and salivary gland tissue (two studies) and were administered intravenously (three studies), intra-glandularly (11 studies) or subcutaneously (one study). No serious adverse events were reported. The overall effect on SFR was significantly increased with a standardized mean difference (SMD) of 6.99 (95% CI: 2.55-11.42). Studies reported improvements in acinar tissue, vascular areas and paracrine factors. CONCLUSION: In conclusion, this systematic review and meta-analysis showed a significant effect of MSC therapy for restoring SG functioning and regenerating SG tissue following radiotherapy in preclinical in vivo studies without serious adverse events. MSC therapy holds significant therapeutic potential in the treatment of radio-induced xerostomia, but comprehensive, randomized, clinical trials in humans are required to ascertain their efficacy in a clinical setting.


Subject(s)
Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells , Salivary Glands , Salivary Glands/radiation effects , Animals , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Humans , Radiation Injuries/therapy , Radiation Injuries/pathology , Xerostomia/therapy , Xerostomia/etiology
3.
Diagnostics (Basel) ; 14(6)2024 Mar 08.
Article in English | MEDLINE | ID: mdl-38534997

ABSTRACT

This study protocol for a prospective, multicenter, diagnostic, clinical trial describes the integration of transoral and transcervical ultrasonography (US) in the initial clinical work-up of patients referred to tertiary head and neck cancer centers with suspected oropharyngeal cancer. The study evaluates the blinded detection rate of oropharyngeal tumors and their US-estimated size and T-stage before histopathology and cross-sectional imaging are available. Magnetic resonance imaging (MRI) scans will be prospectively rated while blinded to T-site histopathology and US. The primary outcome measures of diagnostic accuracy, including sensitivity, specificity, positive and negative predictive values, and overall accuracy, will be reported for both US and MRI. A sub-analysis of prospectively rated 18F-Fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) scans in patients with clinically suspected unknown primary tumors will also be compared to US and MRI. Secondary outcome measures, including a comparison of tumor size estimation between US, MRI, and CT, will also be reported. This prospective multicenter study will provide clinically impactful information regarding the use of transoral and transcervical US for the diagnostic work-up of oropharyngeal cancer.

4.
Diagnostics (Basel) ; 13(21)2023 Oct 25.
Article in English | MEDLINE | ID: mdl-37958201

ABSTRACT

The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). 68Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen activator receptor (uPAR), a receptor expressed on the surfaces of tumor cells. The aim of this study was to investigate the diagnostic value of uPAR-PET/CT (computerized tomography) in detecting regional metastatic disease in patients with OSCC and OPSCC compared to the current imaging work-up. In this phase II trial, patients with OSCC and OPSCC referred for surgical treatment were prospectively enrolled. Before surgery, 68Ga-NOTA-AE105 uPAR-PET/CT was conducted, and SUVmax values were obtained from the primary tumor and the suspected lymph nodes. Histology results from lymph nodes were used as the standard of truth of metastatic disease. The diagnostic values of 68Ga-uPAR-PET/CT were compared to conventional routine preoperative imaging results (CT and/or MRI). The uPAR expression in resected primary tumors and metastases was determined by immunohistochemistry and quantified digitally (H-score). A total of 61 patients underwent uPAR-PET/CT. Of the 25 patients with histologically verified lymph node metastases, uPAR-PET/CT correctly identified regional metastatic disease in 14 patients, with a median lymph node metastasis size of 14 mm (range 3-27 mm). A significant correlation was found between SUVmax and the product of the H-score and tumor depth (r = 0.67; p = 0.003). The sensitivity and specificity of uPAR-PET/CT in detecting regional metastatic disease were 56% and 100%, respectively. When added to CT/MRI, uPAR-PET was able to upstage 2/11 (18%) of patients with occult metastases and increase the sensitivity to 64%. The sensitivity and specificity of 68Ga-NOTA-AE105 uPAR-PET/CT were equivalent to those of CT/MRI. The significant correlation between SUVmax and uPAR expression verified the target specificity of 68Ga-NOTA-AE105. Despite the target specificity, the sensitivity of imaging is too low for nodal staging and it cannot replace neck dissection.

5.
Hematol Oncol ; 40(2): 160-171, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35104916

ABSTRACT

Lymphomas of the nasal cavity and paranasal sinuses (NPS) are rare. Knowledge on sinonasal B-cell lymphoma (SNBCL) primarily comes from case series or single-center studies on small cohorts. We sought to determine the subtype distribution, clinical characteristics, disease behavior, and prognosis on a nationwide scale, with an emphasis on prognostic factors for the most common sinonasal lymphoma, primary sinonasal diffuse large B-cell lymphoma (PSDLBCL). We collated all data from medical records and national databases on patients registered with SNBCL from 1980 through 2018 in the national pathology registry and collected all tissue samples for validation of diagnosis. We included 205 patients and found 10 different subtypes of lymphoma. Diffuse large B-cell lymphoma (DLBCL) was the predominant subtype (80%). The incidence of SNBCL was 0.14/100,000 person-years. The five-year progression-free survival (PFS) and overall survival rates for PSDLBCL were 50% and 56%, respectively. For PSDLBCL, Rituximab showed a statistically significant effect (Hazard Ratio 0.22, p < 0.001), whereas consolidative radiotherapy combined with immunochemotherapy was of limited value (PFS, p = 0.93). When treatment failure occurred, DLBCL showed a distinct pattern of recurrence/dissemination to the NPS, skin, breast, central nervous system (CNS), and/or testis. Collectively, DLBCL comprised a clear majority of SNBCLs, although nine other subtypes were represented. Data showed that immunochemotherapy increased survival for PSDLBCL and that the addition of radiotherapy did not benefit patients. Furthermore, treatment failure for sinonasal DLBCL showed a possible common pathogenesis with primary extranodal lymphomas of specific locations (e.g., CNS, skin, breast, and testis).


Subject(s)
Lymphoma, Large B-Cell, Diffuse , Paranasal Sinus Neoplasms , Cohort Studies , Humans , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/therapy , Male , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/epidemiology , Paranasal Sinus Neoplasms/therapy , Prognosis , Retrospective Studies , Rituximab/therapeutic use , Survival Rate
6.
Viruses ; 15(1)2022 12 22.
Article in English | MEDLINE | ID: mdl-36680074

ABSTRACT

Second primary cancer (SPC) is the second most common cause of death among patients diagnosed with head and neck cancer. This study examined the risk of SPC following oropharyngeal squamous cell carcinoma (OPSCC) and the impact of human papillomavirus (HPV) on survival following SPC. The study was a population-based, retrospective study including all patients diagnosed with OPSCC in eastern Denmark from 2000-2020 who received curative intended treatment. The incidence rate ratio (IRR), age-adjusted incidence rates (AAIR), and hazard ratios (HR) were calculated. A total of 2584 patients with primary OPSCC were included (median follow-up time: 3.1 years), with 317 patients (12.3%) diagnosed with SPC. The risk of SPC was approximately five times the occurrence of cancer in the general population (IRR: 4.96). The median time to SPC after a primary OPSCC was 2.0 years (interquartile range (IQR) = 0.6-4.2 years). HPV-positive (HPV+) patients had a significantly longer median time to SPC, and a significant better survival compared to HPV-negative (HPV-) patients. SPC was most frequently found in lungs, head, and neck (LHN) for HPV- OPSCC patients and lungs followed by gender-specific (prostate, ovaries, or endometrium) for HPV+ OPSCC. There was a significant difference between the two groups when distributed between "within" or "outside" LHN. Patients with SPC outside LHN had a significant better overall survival. This knowledge should be considered during post-treatment surveillance and might guide targeted imaging.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Neoplasms, Second Primary , Oropharyngeal Neoplasms , Papillomavirus Infections , Male , Female , Humans , Squamous Cell Carcinoma of Head and Neck , Retrospective Studies , Incidence , Oropharyngeal Neoplasms/epidemiology , Oropharyngeal Neoplasms/pathology , Human Papillomavirus Viruses , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/pathology , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Papillomavirus Infections/therapy , Neoplasms, Second Primary/epidemiology , Papillomaviridae/genetics
7.
Viruses ; 13(12)2021 12 06.
Article in English | MEDLINE | ID: mdl-34960721

ABSTRACT

Previously, human papillomaviruses were best known for causing diseases in the genital tract, where high-risk types may cause, e.g., cancer of the cervix uteri, while low risk types could cause condylomas [...].


Subject(s)
Head and Neck Neoplasms/virology , Papillomaviridae/physiology , Papillomavirus Infections/virology , Head/virology , Head and Neck Neoplasms/prevention & control , Humans , Neck/virology , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/immunology
8.
Viruses ; 13(7)2021 07 09.
Article in English | MEDLINE | ID: mdl-34372532

ABSTRACT

Significant variation in human papillomavirus (HPV) prevalence in oropharyngeal squamous cell carcinoma (OPSCC) across countries ranging from 11% in Brazil to 74% in New Zealand has been reported earlier. The aim of this study was to systematically review the most recently published studies on the occurrence of HPV in OPSCC globally. PubMed and Embase were systematically searched for articles assessing the occurrence of HPV+ OPSCC published between January 2016 and May 2021. Studies with a study period including 2015 and the following years were included. Both HPV DNA and/or p16 were accepted as indicators of HPV+ OPSCC. 31 studies were enrolled comprising 49,564 patients with OPSCC (range 12-42,024 patients per study) from 26 different countries covering all continents. The lowest occurrences of HPV+ OPSCC were observed in India (0%) and Spain (10%) and the highest occurrences were observed in Lebanon (85%) and Sweden (70%). We observed great variation in HPV prevalence in OPSCC worldwide varying from 0% to 85%. The highest occurrences of HPV+ OPSCC were found in general in Northern European countries, USA, Lebanon, China, and South Korea. We observed a trend of increase in HPV-positivity, indicating a mounting burden of HPV+ OPSCC.


Subject(s)
Alphapapillomavirus/pathogenicity , Squamous Cell Carcinoma of Head and Neck/epidemiology , Squamous Cell Carcinoma of Head and Neck/virology , Alphapapillomavirus/genetics , Global Health/trends , Humans , Oropharyngeal Neoplasms/epidemiology , Oropharyngeal Neoplasms/metabolism , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/virology , Prevalence , Prognosis , Squamous Cell Carcinoma of Head and Neck/pathology
9.
Thyroid ; 31(10): 1523-1530, 2021 10.
Article in English | MEDLINE | ID: mdl-34102860

ABSTRACT

Background: In risk assessment of recurrence, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are often grouped together as differentiated thyroid cancer (DTC). However, while risk factors affecting recurrence of PTC are well established, risk factors for recurrence of FTC are not. This systematic review examines risk factors for recurrence of FTC and evaluates their significance. Methods: A systematic search on PubMed and Embase was performed in September 2020, including studies evaluating risk factors for recurrence of FTC. A quality assessment of the enrolled studies was performed. Results: Nine studies (n = 1544 patients) from eight countries were included. The average recurrence rate was 13.6%, and distant metastasis (DM) constituted 64.8% of the recurrent cases. The risk factors examined were sex, age at diagnosis, primary tumor size, degree of invasiveness, focality, positive resection margin, lymph node (LN) metastasis, and DM at diagnosis. Risk factors correlated with recurrence of FTC were age older than 45 years, primary tumor size above 40 mm, widespread invasion, multifocality, positive resection margin, LN metastasis, and DM at diagnosis. Sex was not a statistically significant risk factor. Conclusions: We identified seven risk factors associated with recurrence of FTC. Age and multifocality were found to be of greater impact regarding recurrence risk of FTC compared with PTC. Future research needs to address the impact of different risk factors for recurrence of FTC particularly including age, primary tumor size, angioinvasion, and mutational status.


Subject(s)
Adenocarcinoma, Follicular/etiology , Neoplasm Recurrence, Local/etiology , Risk Assessment , Thyroid Neoplasms/etiology , Adenocarcinoma, Follicular/blood supply , Adenocarcinoma, Follicular/pathology , Adult , Age Factors , Aged , Female , Humans , Male , Middle Aged , Neoplasm Invasiveness , Neovascularization, Pathologic , Risk Factors , Thyroid Neoplasms/blood supply , Thyroid Neoplasms/pathology
10.
Ear Nose Throat J ; 100(5_suppl): 554S-561S, 2021 Sep.
Article in English | MEDLINE | ID: mdl-31801366

ABSTRACT

The immune pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) remains obscure. Our aim was to compare humoral immunity and white blood cell counts in patients with CRSwNP and controls. A prospective case-control study was carried out in 37 patients with CRSwNP and 34 controls without CRS. Clinical data were gathered through a systematic interview. Computed tomography scan, skin prick test, spirometry, and immunological parameters (leukocyte differential count, immunoglobulin classes, and immunoglobulin [Ig] G subclasses) in serum specimens were obtained. Statistical analysis was performed using SPSS v.23. The prevalence of chronic lower respiratory diseases was greater in the CRSwNP group (P < .001), but atopic disease had no significant difference. A significantly higher eosinophil (P < .001) and basophil relative count (P = .022) and a lower relative neutrophil count (P = .013) were found among CRSwNP group. Patients with CRSwNP had higher IgG1 (P = .022), but lower IgG2 (P = .014) and IgG3 (P = .018) serum levels compared to controls; IgG4, total IgG, IgA, IgM, and IgE serum levels did not differ between groups, as well as the prevalence of immunoglobulin classes or IgG subclasses deficiency. The variation observed in peripheral relative leukocyte count and the systemic IgG1 subclass shift are similar to what is known to happen in nasal polyp tissue. A unique systemic immune profile seems to be present in patients with CRSwNP.


Subject(s)
Immunity, Humoral/immunology , Immunoglobulin Isotypes/blood , Nasal Polyps/immunology , Rhinitis/immunology , Sinusitis/immunology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Chronic Disease , Female , Humans , Leukocyte Count , Male , Middle Aged , Nasal Polyps/blood , Prospective Studies , Rhinitis/blood , Sinusitis/blood , Skin Tests
11.
Acta Oncol ; 59(9): 1131-1136, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32406799

ABSTRACT

Background: We aimed to review systematically the literature on locoregional recurrence rates in patients with HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC).Methods: PubMed and Embase databases were systematically searched using key words such as human papillomavirus, oropharyngeal squamous cell carcinoma with local, regional, and locoregional recurrence.Results: Nine studies (2974 patients with known HPV-status, 59% HPV-positive) were included. Among the HPV-positive and -negative patients, 69% and 58% had lymph node metastasis at diagnosis. At a median time to recurrence ranging from 8.4 to 13.2 months among the included studies, we found that a weighted average of 9% and 26% for HPV-positive and -negative patients experienced locoregional recurrence. Overall, the median follow-up time ranged from 21 to 83 months among the included studies.Conclusion: Recurrence rates for HPV-positive and -negative OPSCC patients were 9% and 26%, respectively, equating to an almost three times higher rate of locoregional recurrence among HPV-negative patients compared to HPV-positive patients.


Subject(s)
Alphapapillomavirus/isolation & purification , Neoplasm Recurrence, Local/epidemiology , Oropharyngeal Neoplasms/therapy , Papillomavirus Infections/epidemiology , Squamous Cell Carcinoma of Head and Neck/therapy , Follow-Up Studies , Humans , Incidence , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/pathology , Lymphatic Metastasis/therapy , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/virology , Oropharyngeal Neoplasms/pathology , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/diagnosis , Papillomavirus Infections/pathology , Prognosis , Risk Assessment/statistics & numerical data , Risk Factors , Squamous Cell Carcinoma of Head and Neck/pathology , Squamous Cell Carcinoma of Head and Neck/virology , Time Factors
12.
Ugeskr Laeger ; 181(41)2019 Oct 07.
Article in Danish | MEDLINE | ID: mdl-31610833

ABSTRACT

Recurrent respiratory papillomatosis (RRP) is a condition with benign tumours in the respiratory tract. RRP ensues in both children and adults. The disease is induced by low-risk human papillomavirus (HPV) types HPV-6 and HPV-11. RRP have a recurrent nature with symptoms ranging from hoarseness, dyspnoea, and dysphagia to life-threatening airway obstructions. Currently, no medical curative treatment of RRP is available, however, the literature indicates, that the HPV-vaccines could protect against RRP by preventing genital warts.


Subject(s)
Papillomavirus Infections , Papillomavirus Vaccines , Respiratory Tract Infections , Adult , Child , Humans , Papillomavirus Infections/diagnosis , Papillomavirus Infections/therapy , Papillomavirus Vaccines/therapeutic use , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/therapy
13.
Ugeskr Laeger ; 181(17)2019 Apr 22.
Article in Danish | MEDLINE | ID: mdl-31036136

ABSTRACT

This is a review discussing evaluation and management of paediatric nasal fractures, which have been reported as one of the three most common facial bone fractures. Nasal fractures in children are usually treated with closed reduction after 3-5 days, while other injuries like septal haematoma must be treated at the initial presentation. It is important to pay careful attention to the nasal anatomy during the surgical management of paediatric nasal injuries, as disturbing the nasal growth zones can have an impact on future nasal development.


Subject(s)
Nasal Bone , Skull Fractures , Child , Humans , Nasal Bone/injuries , Nose , Skull Fractures/therapy
14.
Ugeskr Laeger ; 180(47)2018 Nov 19.
Article in Danish | MEDLINE | ID: mdl-30509345

ABSTRACT

Oropharyngeal squamous cell carcinoma (OPSCC) induced by human papillomavirus (HPV) is highly prevalent in the western part of the world. Patients with HPV-induced OPSCC are often younger and have a much better prognosis than patients with HPV-negative OPSCC. The newly introduced transoral robotic surgery offers the ability to perform en bloc tumour resection with good margin control. It may be an alternative to the traditional radiation therapy for early-stage OPSCC. A Danish randomised clinical trial is now aiming at comparing these two treatments with a focus on long-term functional outcomes.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Oropharyngeal Neoplasms , Robotic Surgical Procedures , Carcinoma, Squamous Cell/surgery , Head and Neck Neoplasms/surgery , Humans , Oropharyngeal Neoplasms/surgery , Papillomaviridae , Papillomavirus Infections
15.
Ugeskr Laeger ; 180(47)2018 Nov 19.
Article in Danish | MEDLINE | ID: mdl-30509346

ABSTRACT

The aim of this review is to evaluate current guidelines for diagnosis, treatment and follow-up of patients with chronic rhinosinusitis. We discuss: 1) diagnostic criteria, 2) the use of supplementary tools like visual analogue scale, Sino-Nasal Outcome Test and Sniffin' Sticks, 3) the use of tests like allergy, serum IgE and biopsy and 4) comorbidity in relation to the unified airways concept. Furthermore, we evaluate: 1) initial treatment with topical steroids and nasal irrigation, 2) additional treatment options including surgery, systemic steroids and antibiotics and 3) treatment risks. Follow-up of patients is important for evaluating treatment effect and possible need of further treatment.


Subject(s)
Nasal Polyps , Rhinitis , Sinusitis , Chronic Disease , Comorbidity , Humans , Rhinitis/complications , Rhinitis/diagnosis , Rhinitis/therapy , Sinusitis/complications , Sinusitis/diagnosis , Sinusitis/therapy
16.
Ugeskr Laeger ; 180(37)2018 Sep 10.
Article in Danish | MEDLINE | ID: mdl-30259834

ABSTRACT

In this case report, an 81-year-old former carpenter presented with unilateral deteriorating vision. Due to gradual worsening and involvement of the other eye, he was seen by an ophthalmologist and underwent both CT and MRI, which gave rise to suspicion of a sinonasal cancer. Nasal endoscopy revealed a tumour in the ethmoid bilaterally, and a biopsy showed intestinal type adenocarcinoma. This type of cancer is rare, but strongly associated with occupational exposure to wood dust. Symptoms are usually vague, and the diagnosis is made with some delay, which is reflected in a poor prognosis.


Subject(s)
Adenocarcinoma , Paranasal Sinus Neoplasms , Vision Disorders/etiology , Adenocarcinoma/complications , Adenocarcinoma/diagnosis , Adenocarcinoma/diagnostic imaging , Aged, 80 and over , Dust , Humans , Magnetic Resonance Imaging , Male , Paranasal Sinus Neoplasms/complications , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/diagnostic imaging , Wood/adverse effects
17.
Ugeskr Laeger ; 180(38)2018 09 17.
Article in Danish | MEDLINE | ID: mdl-30259840

ABSTRACT

Sinonasal cancer is rare, and the symptoms are often vague leading to a delay in diagnosis which affects the prognosis. This cancer type is most common in elderly men, and it consists of many different histological types, mainly carcinomas. The risk factors remain elusive, except for an association between intestinal type adenocarcinoma and exposure to wood dust. Human papillomavirus may play a role in squamous cell carcinomas. The treatment of choice is surgery, often combined with radiotherapy. Most surgeries are endoscopic (image-guided) to secure complete resection in a complex anatomic region.


Subject(s)
Paranasal Sinus Neoplasms , Aged , Humans , Male , Nasal Cavity/pathology , Neoplasm Staging , Papillomaviridae , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/therapy , Paranasal Sinus Neoplasms/virology
18.
Curr Diabetes Rev ; 14(4): 327-333, 2018.
Article in English | MEDLINE | ID: mdl-28201967

ABSTRACT

INTRODUCTION: Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation. Angiotensin converting enzymeinhibitors are widely known to cause angioedema but less is known about the association between dipeptidyl peptidase-4 inhibitors (gliptins) and angioedema. Dipeptidyl peptidase-4 inhibitors are antidiabetic drugs used to improve glycaemic control. They, as a class effect, inadvertently affect the degradation of the vasoactive kinins bradykinin and substance P, both of which can cause angioedema due to vasodilatation and increase in vascular permeability in the capillaries. OBJECTIVE: To assess the risk and pathomechanism of angioedema due to inhibition of dipeptidyl peptidase- 4 inhibitors when used as monotherapy and in combination with angiotensin converting enzymeinhibitors. METHOD: PubMed, Embase, the Cochrane Library, PubMed Central, Web of Science, Google Scholar and clinicaltrials.gov were searched using different combinations of keywords "angioedema", "dipeptidyl peptidase 4", "dipeptidyl peptidase 4 inhibitors", "gliptins", "bradykinin", "substance P" and "angiotensin converting enzyme-inhibitors". Original research papers were preferably used as references and their bibliographies were used to further the search for original research results. RESULTS: Both angiotensin converting enzyme and dipeptidyl peptidase-4 are major enzymes in the degradation pathway of bradykinin and substance P, and when inhibited pharmacologically - especially at the same time - the theoretical risk of angioedema is increased due to accumulation of vasoactive kinins. CONCLUSION: Treatment with dipeptidyl peptidase-4 inhibitors must be carefully considered and monitored especially during concurrent treatment with angiotensin converting enzyme-inhibitors or when treating patients with a known predisposition to angioedema.


Subject(s)
Angioedema/chemically induced , Dipeptidyl Peptidase 4/metabolism , Dipeptidyl-Peptidase IV Inhibitors/adverse effects , Angioedema/enzymology , Angioedema/genetics , Angioedema/physiopathology , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Animals , Bradykinin/metabolism , Capillary Permeability , Drug Interactions , Genetic Predisposition to Disease , Humans , Prognosis , Proteolysis , Risk Factors , Substance P/metabolism , Vasodilation
19.
J Craniofac Surg ; 29(1): 212-216, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29287000

ABSTRACT

Computed tomography (CT) images have been used in very few studies on distances to the ethmoidal arteries in the orbit. Most other studies have included direct measurements on cadavers and frequently quote the 24-12-6 mm rule to describe distances from the anterior lacrimal crest to the anterior and posterior ethmoidal foramina (AEF and PEF), optic canal (OC), respectively. However, the large interindividual variation of distances renders absolute values less applicable in a clinical setting. Preoperative measurements on CT images may provide more precise distances than absolute rules and thus lead to safer orbital surgery. The authors hypothesize that the distances to the ethmoidal arteries and the length of the medial wall are positively correlated and that measurements of the distances from the posterior lacrimal crest (PLC) on CT images are feasible with a low intra- and interobserver variability.Fifty intact orbits from 25 Caucasian cadavers were exenterated and examined. In additional, high-resolution CT scans of 48 orbits from 24 other Caucasian nonexenterated cadavers were examined. Distances were measured from 4 different anterior landmarks to the AEF and PEF and the OC.Distances from the most anterior landmarks to the arteries were positively correlated with the length of the medial wall. Measurements of the distances from the PLC to the ethmoidal arteries on CT images were feasible with a low intra- and interobserver variability. In conclusion, iatrogenic damage to the ethmoidal arteries in the orbit may be best avoided by using CT measurements in presurgical planning.


Subject(s)
Arteries/anatomy & histology , Ethmoid Bone/blood supply , Orbit/anatomy & histology , Aged , Cadaver , Ethmoid Bone/anatomy & histology , Ethmoid Bone/diagnostic imaging , Female , Humans , Male , Middle Aged , Orbit/blood supply , Orbit/diagnostic imaging , Tomography, X-Ray Computed , White People
20.
Ugeskr Laeger ; 179(25)2017 Jun 19.
Article in Danish | MEDLINE | ID: mdl-28648153

ABSTRACT

The prevalence of oropharyngeal cancer is increasing in the Western world, and human papillomavirus (HPV) is believed to play a role in this development. Patients with HPV-positive oropharyngeal cancer differ significantly from patients with HPV-negative cancer. They may present solely with a small cervical metastasis and thus undergo an extensive diagnostic workup. Treatment modalities include radiotherapy often in combination with chemotherapy. However, new surgical advances are now possible. In this review we discuss the changing epidemiology, virology, symptomatology and different treatment modalities.


Subject(s)
Oropharyngeal Neoplasms/virology , Papillomavirus Infections/complications , Adolescent , Adult , Chemoradiotherapy , Female , Humans , Male , Middle Aged , Oropharyngeal Neoplasms/diagnosis , Oropharyngeal Neoplasms/epidemiology , Oropharyngeal Neoplasms/therapy , Papillomaviridae , Papillomavirus Infections/diagnosis , Papillomavirus Infections/epidemiology , Papillomavirus Infections/therapy , Papillomavirus Vaccines/administration & dosage , Sexuality
SELECTION OF CITATIONS
SEARCH DETAIL